Changes in anti-citrullinated protein antibody isotype levels in relation to disease activity and response to treatment in early rheumatoid arthritis

Alf Kastbom, Karin Roos Ljungberg, Michael Ziegelasch, Jonas Wetterö, Thomas Skogh and Klara Martinsson

The self-archived postprint version of this journal article is available at Linköping University Institutional Repository (DiVA):
http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-153152

N.B.: When citing this work, cite the original publication.

Original publication available at:
https://doi.org/10.1111/cei.13206

Copyright: Wiley (12 months)
http://eu.wiley.com/WileyCDA/
Changes in anti-citrullinated protein antibody isotype levels in relation to disease activity and response to treatment in early rheumatoid arthritis

Short title: ACPA isotypes and disease course in early RA

Alf Kastbom, Karin Roos Ljungberg, Michael Ziegelasch, Jonas Wetterö, Thomas Skogh, Klara Martinsson*

Division of Neuro and Inflammation Sciences, Department of Clinical and Experimental Medicine, Faculty of Medicine and Health Sciences, Linköping University, Linköping. Sweden

alf.kastbom@liu.se, karin.roosljungberg@ltdalarna.se,
michael.ziegelasch@regionostergotland.se, jonas.wettero@liu.se, thomas.skogh@liu.se

and klara.martinsson@liu.se

*Corresponding author:
Dr Klara Martinsson

AIR/Rheumatology, Entrance No. 69, floor 10
Keywords:
Rheumatoid arthritis (RA), Immunoglobulin (Ig) isotypes, anti-citrullinated protein antibodies (ACPA), longitudinal analyses, disease course

List of abbreviations
ACPA anti-citrullinated protein antibodies
ACR-87 American College of Rheumatology 1987 RA-classification criteria
CCP cyclic citrullinated peptide
DAS28 disease activity score 28
DMARDs disease-modifying anti-rheumatic drugs
ELIA/ELISA enzyme-linked immunosorbent assay
EULAR European League Against Rheumatism
HRP horseradish peroxidase
Ig Immunoglobulin
RA Rheumatoid Arthritis
SC secretory component
SIgA secretory IgA
TIRA-2 Early Intervention in Rheumatoid Arthritis
TNF tumor necrosis factor alpha
Summary

Rheumatoid arthritis (RA) is a chronic inflammatory disease where serum analysis of anti-citrullinated peptide/protein antibodies (ACPA) is an important diagnostic/prognostic tool. Levels and changes of ACPA in RA patients have previously been studied in relation to disease course and therapy response, but less is known regarding ACPA isotype changes in early RA. Hence, recent-onset RA patients (n=231) were subjected to a 3-year clinical and radiological follow-up. Serum samples were serially collected and ACPA isotypes were analysed using the 2nd generation CCP as capture antigen. Changes in ACPA isotype levels and status were related to disease course and pharmacotherapy. At inclusion, 74% of the patients tested positive for ACPA IgG; 55% for IgA, 37% for secretory IgA (SIgA) and 35% for IgM. The proportion of positive patients decreased significantly at follow-up regarding ACPA SIgA, IgM and IgA. During the initial 3 months, reduction of the 28-joint disease activity score (DAS28) correlated with reduced levels of ACPA IgG (Rho=0.242, P=0.003), IgA (Rho=0.260, P=0.008), IgM (Rho=0.457, P<0.001) and SIgA (Rho=0.402, P<0.001). Levels of ACPA SIgA (P=0.008) and IgM (P=0.021) decreased significantly among patients with good response to treatment, which was not seen regarding ACPA IgA or IgG. Changes in ACPA isotype levels associated not with radiographic damage. In conclusion, ACPA SIgA and IgM declined rapidly upon anti-rheumatic therapy and correlated with decreased disease activity in recent-onset RA. This may indicate that down-regulation of mucosal immunity to citrullinated proteins/peptides and recruitment of new B cells, are key features of therapy responses in early RA.
Introduction

Rheumatoid arthritis (RA) is a chronic inflammatory disease, where genetic as well as environmental factors are of importance regarding disease development. RA patients are commonly subdivided according to the presence or absence of circulating IgG anti-citrullinated protein antibodies (ACPA). The presence of ACPA identifies patients at increased risk of a severe disease course [1] and there is solid evidence that both environmental and genetic associations differ between ACPA-positive and ACPA-negative cases [2-4]. In clinical routine, typically only serum ACPA IgG is analysed, but serum ACPA of IgM- and IgA-class are also present in 30-60% of early RA cases [5, 6].

ACPA may contribute to RA pathogenesis in different ways depending on isotype. ACPA IgG may trigger inflammation by Fc-gamma receptor ligation and/or classical complement activation, which may be enhanced by altered glycosylation patterns of ACPA IgG [7]. ACPA IgM has been reported to induce cell-activating properties following complement activation [8]. The half-life of circulating IgM is short, and the fact that ACPA IgM has been detected in patients with longstanding RA suggests continuous recruitment of naïve B-cells [9]. ACPA IgA does not activate the classical complement pathway, but may exert dual effects after ligation to Fc-alpha receptors expressed on cell-surfaces [10, 11]. We previously reported that patients with recent-onset RA testing double seropositive for IgA- and IgG-class ACPA at baseline suffered from a more severe disease course compared to patients positive for ACPA IgG alone [5, 12].
Circulating IgA is mainly produced in the bone marrow, whereas secretory IgA (SIgA) is produced at mucosal surfaces where it serves as a first line of defense [13, 14]. In humans, circulating IgA is mainly monomeric, while SIgA is a dimeric or polymeric molecule linked together by a joining chain (J-chain) and complexed with secretory component (SC) [14]. We have recently shown that ACPA SIgA can be detected not only in mucosal fluids [15], but also in sera from recent-onset RA patients [15, 16].

Changes in ACPA levels and specificities have been extensively studied in relation to disease course and therapeutic response in established RA [17], but the associations to clinical outcomes have not been strong enough to justify repeated analyses in clinical routine. The temporal resolution of ACPA isotype dynamics has not previously been thoroughly characterized in early RA, despite possible associations with disease induction, course and outcome. Hence, in the present study, we investigated ACPA of IgG-, IgA-, IgM- and SIgA-class in serially collected serum samples from a well defined cohort of recent-onset RA patients, and related changes in ACPA levels to treatment and disease course during 3 years.

Materials and methods

Subjects

The TIRA-2 cohort (Swedish acronym for the 2nd ‘Early Intervention in Rheumatoid Arthritis’ cohort) enrolled patients with recent-onset RA (<12 months since first observed joint-swelling according to the patients' judgement) at six rheumatology clinics in southeast/mid Sweden between 2006 and 2009 [16]. Patients fulfilled either the American
College of Rheumatology 1987 RA-classification criteria (ACR-87) [18], or a more liberal set of criteria to enable inclusion of earlier RA cases (morning stiffness ≥ 60 minutes, symmetrical palpable synovitis, and arthritis in hands or feet (wrists, metacarpophalangeal, proximal interphalangeal, metatarsophalangeal joints).

The patients had neither received disease-modifying anti-rheumatic drugs (DMARDs) prior to the baseline visit. Serum samples were taken at inclusion (0 months), 3 months, 12 months and 36 months, and stored at -70°C until analysed. To study the longitudinal response of ACPA isotypes (IgG, IgA, IgM and SIgA) we identified only the patients who had serum samples available from all visits (n=231, 46% of the entire TIRA-2 cohort). Baseline patient characteristics are summarised in Table 1 and Table 2. Follow-up visits including 28-joint disease activity score (DAS28) [19] and self-reported pain on a 100mm visual analogue scale (VAS) was scheduled at 3, 12 and 36 months (patient characteristics on clinical parameters shown in S1). Therapy during follow-up was instituted as found appropriate by the treating physician, at the baseline visit, according to current practice in Sweden. Response to therapy was categorised according to the European League Against Rheumatism (EULAR) response criteria [20]. The study protocol was approved by the regional ethics review board (Linköping, Sweden (decision number M168-05), and all participating subjects gave a written informed consent.

**ACPA detection**

All ACPA isotypes were detected by immunoassays using the 2nd generation cyclic citrullinated peptide (CCP) as antigen. ACPA SIgA and IgM were measured by modifying commercially available anti-CCP ELISA kits (Euro-Diagnostica, Malmö, Sweden). Serum samples were diluted 1:25, added to pre-coated CCP microtitre plates...
and incubated for 1 hour. Following washing, HRP-conjugated polyclonal goat anti-human SIgA (detects free and bound secretory component) and IgM (detects the heavy chain) antibodies respectively (Nordic Biosite, Täby, Sweden) were used to detect SIgA anti-CCP (dilution 1:2000) and IgM (1:10 000). Incubation was arrested with 0.5M H₂SO₄ and read at 450 nm with 650nm as reference wavelength (TECAN Sunrise, software: Magellan V7.1; Tecan Nordic AB, Mölndal, Sweden). A seven-step serial dilution was used for standard curve calculations using patient sera with high levels of anti-CCP SIgA and anti-CCP IgM, respectively. Samples were analysed in duplicates using the mean value. The intra- and inter-assay variation in the ACPA SIgA ELISA was 1% and 10%, respectively and 2% and 17% in the ACPA IgM ELISA, which was determined using 3 samples with the assay repeated 3 times. Control serum samples from healthy blood donors (50 females, 50 males; mean age 46 years) were collected in 2010 and used to determine the cut-off for positive tests. Healthy controls often display low levels of the analysed antibodies but by setting the cut-off values using the 99th percentile among the controls (anti-CCP SIgA 3089 AU/mL and anti-CCP IgM 6032 AU/mL) this problem do not apply.

Serum ACPA IgA and IgG were analysed by a fluoroenzyme immunoassay (EliATM Thermo Fisher Scientific, PhaDia AB, Uppsala, Sweden) as described previously [21]. The cut-off level for a positive ACPA IgA test was set at the 99th percentile of healthy blood donors (2 µg/L). For ACPA IgG analyses, we used the cut-off point suggested by the manufacturer (7U/mL).

**Radiographic analyses**
Baseline and 3-year follow-up radiographs of hand and feet were available from 155 out of the 231 patients selected for the present study. The 155 patients with radiographs available were slightly younger than those without (mean age 56 vs 60 years, P=0.014), while the remaining baseline characteristics (Table 1) were not significantly different. Joint damage was evaluated in chronological order by one experienced reader (MZ) according to the Larsen-Dahle method [22].

Statistical analyses

Statistical analyses were performed using SPSS Statistic version 23 (IBM, Armonk, NY, USA) and Prism version 6.0c (Graphpad Software Inc, La Jolla, CA, USA). P-values <0.05 were regarded as statistically significant. Differences in proportions were analysed using McNemar test. Differences within isotype levels during the follow-up were analysed using Friedman test. Kruskal-Wallis test was used to test differences between the relative changes in antibody level across isotypes and Dunn’s multiple comparisons test was used as post-hoc analysis. When investigating the impact of the change in antibody levels among the four isotypes in relation to disease course, we selected only patients who were isotype positive at inclusion. Spearman test were used to compare changes in relative antibody levels with changes in DAS28 and its components, VAS pain, and radiographic damage, respectively. Mann-Whitney test was used to analyse differences in DAS28 change and radiographic damage compared to patients displaying 1 ACPA vs. 2 or more ACPAs. Differences in the score for radiographic damage between patients remaining ACPA positive and patients becoming ACPA negative were tested using Mann-Whitney test.
Differences in relative mean antibody levels change across European League Against Rheumatism (EULAR) response criteria and differences in relative mean antibody change versus treatment were tested using Mann-Whitney test.

Results

Dynamics of ACPA isotypes in early RA

At inclusion, 74% of the patients tested positive for ACPA IgG and 55% for ACPA IgA (Figure 1), and the proportion of positive patients did not differ significantly between inclusion and any time-point during follow-up.

Regarding ACPA SIgA, 37% of the patients tested positive at inclusion, and 33% (28/85) of these turned negative during follow-up, resulting in a significantly lower proportion of positive patients (P<0.0001 for baseline versus month 3, 12, and 36, respectively) (Figure 1). 35% tested positive at baseline for ACPA IgM and 30% (24/81) of these had become negative at month 3, resulting in a significantly lower proportion of positive patients (P<0.0001). This remained similar at months 12 and 36, and month 12 and 36 was significantly different from baseline (P=0.003 and P=0.002, respectively; Figure 1). 52 % of the patients were ACPA IgA positive at baseline which was a significantly higher percentage compared to month 3 when 11% (13/120) of these patients had become negative (P=0.007). At month 12 13% had become ACPA IgA negative (16/120, P=0.002). In contrary, the percentage of patients remaining ACPA IgG positive also remained similar during the follow-up (Figure 1).
53% of the ACPA SIgA positive patients showed high antibody level (defined as 2 times above the cut off level) and in ACPA IgM and IgA these percentages were 61% and 70%, respectively. For ACPA IgG as much as 98% of the positive patients showed high antibody levels. 18% were positive in 1 ACPA isotype, 20% were positive in 2 different ACPAs, 9% in 3 different ACPAs and 29% displayed all 4 ACPAs (S2).

Antibody levels of all the four isotypes had decreased at month 3, 12 and 36 as compared with baseline (P=0.0001) (Figure 2). There were no significant differences in ACPA isotype levels between month 3, 12 and 36 of follow-up.

Among patients testing negative for ACPA IgG, IgA, SIgA and IgM at inclusion, 1% turned positive during the 36 months of follow-up regarding ACPA IgG, 2% became SIgA- or IgM-positive, and 3% became IgA-positive.

When comparing the relative change in antibody levels between ACPA isotypes, levels differed significantly between inclusion and month 3 (P<0.0001). As illustrated in Figure 3, post-hoc analyses showed that the relative change in antibody levels between inclusion and month 3 were most pronounced regarding ACPA SIgA and IgM levels compared to ACPA IgG (P<0.0001 for both, Figure 3). ACPA SIgA and IgM relative antibody change were also more pronounced compared to ACPA IgA (P<0.001 and P<0.05, respectively). Relative changes between ACPA SIgA and IgM levels did not differ significantly, while ACPA IgA showed a greater decrease in relative antibody
level compared to ACPA IgG (P<0.05) (Figure 3). The relative change in ACPA antibody level did neither differ between month 3 and 12 nor between month 12 and 36.

**Relative changes in ACPA isotypes levels and disease course**

During the initial 3 months, the relative decrease in ACPA IgG, IgA, IgM and SIgA levels correlated significantly with reduction in DAS28 (Table 3). DAS28 reduction did not differ between patients displaying 1 ACPA isotype compared to patients displaying 2 or more ACPA isotypes (P=0.972). After month 12, only ACPA IgG remained significantly correlated with changes in DAS28 (Table 3). As shown in Figure 3, changes in antibody levels were more pronounced between inclusion and month 3. We therefore analysed the change in DAS28 components during the first 3 months. The decrease in ACPA SIgA and IgM levels during the first 3 months showed weak to moderate statistically significant correlations with all DAS28 components and self-reported pain (Table 4). The change in ACPA IgA and IgG levels correlated with change in swollen joint count. In addition, the change in ACPA IgA levels correlated with the change in CRP and with the change in patient’s global assessment. On the other hand, the change in ACPA IgG levels correlated with the change in tender joint count and VAS pain (Table 4). Of the ACPA isotypes analysed, only the change in ACPA IgG and SIgA levels between inclusion and month 12 correlated with the change in HAQ (ACPA IgG rho=0.227, P=0.006 and ACPA IgA, rho=0.245, P=0.041).

During the first 3 months, we also categorized the DAS28 change according to the EULAR response criteria. The mean change of ACPA SIgA decreased significantly
more among patients (n=46) with a good EULAR response as compared to those patients (n=19) with no EULAR response (50% vs 31%; P=0.008). A similar difference was seen regarding ACPA IgM, where good responders (n=45) had a mean decrease of 45% as compared to 31% among those patients (n=14) with no EULAR response (P=0.021). There were no differences in the mean change of ACPA SIgA and IgM levels between patients with moderate and no EULAR response. The mean change in ACPA IgA and IgG levels did not differ according to EULAR response (data not shown).

**Changes in ACPA isotypes levels in relation to radiographic joint damage**

For each ACPA isotype, the 3-year radiographic joint damage, as graded by the Larsen score, was compared between patients remaining ACPA positive at 3 months and patients becoming ACPA negative at 3 months. The Larsen score at month 36 did not differ (P=0.57) between patients remaining ACPA IgG positive (4.7±4.3 (mean±SD), n=120) and patients becoming negative (2.0±0, n=1). This was also the case for ACPA IgA (4.3±3.6 vs. 3.7±4.8, n=72 vs. n=14, P=0.31), ACPA IgM (4.4±3.6 vs. 2.9±3.5, n=37 vs. n=18, P=0.11) and ACPA SIgA (4.1±3.7 vs. 4.8±5.9, n=34 vs. n=22, P=0.82). The change in Larsen score during the initial 36 months did not differ between patients remaining positive or becoming negative for any of the ACPA isotypes (ACPA IgG (2.1±2.9 vs. 2.0±0, n=116 vs. n=1, P=0.66 (mean±SD, positive vs. negative)) ACPA IgA (1.8±2.6 vs. 1.6±3.1, n=72 vs. n=13, P=0.45), ACPA IgM (2.0±3.0 vs. 1.6±2.7, n=37 vs. n=18, P=0.46) and ACPA SIgA (1.9±3.1 vs. 1.5±2.4, n= 34 vs. n=22, P=0.65). Likewise, changes in ACPA isotype levels did not correlate significantly with radiographic joint damage at month 36, nor with 36-month progression of joint damage.
However, the Larsen score at month 36 showed a trend of being significant higher in patients positive for 1 single ACPA isotype compared to patients displaying 2 or more (P=0.056) and the score for Larsen progression at 36-month was significantly different in single-positive patients compared to patients with 2 or more ACPA isotypes (P=0.040). However, when adjusting for multiple comparisons this significant difference disappeared.

Changes in relative ACPA isotype levels in relation to treatment

49 out of the 84 (58%) patients positive for ACPA SIgA started treatment with oral corticosteroids at the baseline visit (mean prednisolone dose of 8.9 mg, range 1– 20mg), and in this group the mean change in ACPA SIgA levels between month 0 and 3 were greater compared to non-treated ACPA SIgA positive patients (n=35; 55% vs 30% AU/ml; P<0.0001). Likewise, there was a more pronounced decrease in the mean change of ACPA IgA levels (30% vs 22%; P=0.029) among corticosteroid-treated patients (n=70/120), as well as regarding the mean change of ACPA IgM levels in corticosteroid-treated patients (41% vs 22%; n=45/81; P=0.01). Corticosteroid treatment did not significantly associate with change in ACPA IgG levels. DMARD monotreatment was compared with DMARD combination treatment in patients positive for the respective ACPA isotype. For ACPA SIgA (77% vs 48%; n=9/80, P=0.005) and IgA (47% vs 25%; n=10/114), P=0.022) a combination of DMARDs treatment induced a greater decrease in antibody levels between month 0 and 3 but the change in ACPA IgM and IgG levels were not significantly affected. The effect of biological DMARDs (bDMARDs) could not be analysed since this treatment was very rare within the first year.
Discussion

This observational study presents a detailed longitudinal characterization of ACPA isotypes in relation to disease course in ‘real-world’ early RA. We found clear differences in ACPA isotype responses over time, both in terms of antibody levels and status. The proportion of patients testing positive regarding ACPA SIgA and IgM decreased significantly after start of anti-rheumatic treatment, whereas status of ACPA IgA and IgG remained similar during follow-up. Regarding antibody levels, all tested isotypes decreased during the first 3 months, but remained stable thereafter. Interestingly, levels of ACPA SIgA and IgM showed a more pronounced decrease than ACPA IgG, which remained significant after corrections for multiple comparisons. ACPA SIgA also showed a more substantial decline than ACPA IgA as did ACPA IgM but following corrections for multiple comparisons only ACPA SIgA showed a greater decrease compared to ACPA IgA. The half-life of different isotypes in the circulation differ markedly (21-25 days for IgG compared to 5-6 days for IgA and IgM), which of course could be relevant to the dynamics of ACPA isotypes during the initial 3 months. However, we find this an unlikely explanation to the observed patterns, as ACPA IgA and IgM (where IgA and IgM generally show similar isotype half-lives) displayed differences, whereas ACPA IgA and IgG (where IgA and IgG typically differs in isotype half-lives) did not. Our results are partly in line with results from a smaller cohort reporting decreasing ACPA levels of IgA and IgM, as well as the IgG subclasses apart from IgG1 at 7-years follow-up [6].
In order to identify ACPA isotypes of particular clinical and/or pathogenic interest, we correlated changes of antibody levels to a variety of clinical outcomes. During the initial 3 months, improvement in disease activity was moderately correlated with decrease in ACPA SIgA and IgM levels. Although the ACPA levels overall decreased during the follow-up, the type of treatment appeared to influence the magnitude of the decline. Patients treated with oral corticosteroids or a combination of DMARDs displayed a greater reduction in ACPA SIgA and ACPA IgA levels, whereas a greater change in ACPA IgM levels were only associated with oral corticosteroid treatment. In contrast, the change in ACPA IgG levels was not influenced by either treatment. In RA cases with longer disease duration, it has been shown that add-on treatment primary targeting the adaptive immune system (i.e. anti-CD20 treatment with rituximab or T-cell modulation with abatacept) reduces ACPA levels, which associates with reduced disease activity and improved health [17, 23, 24]. Also, Cambridge et al., showed that both ACPA IgG and IgA decreased after rituximab treatment [25]. After intracellular synthesis, SC is transported to the cell membrane and is then available to bind IgA [26]. Thus, reduced SC expression could lead to lower levels of SIgA. The expression of SC is dependent on TNF [27] induced NF-kappaB activation [28]. TNF inhibition seems to associate with ACPA reductions in early RA [29], but not in established disease [24, 29]. Hence it would be relevant to study the impact of anti-TNF therapy regarding ACPA SIgA levels, but in the current study, the statistical power was insufficient for investigation of any specific impact of bDMARDs on ACPA isotype response. In addition, the reduction of ACPA SIgA and IgA levels appeared greater in patients receiving more aggressive treatment, i.e. conventional synthetic DMARD (csDMARD) in combination or addition of low-dose oral corticosteroids. The glucocorticoid receptor
(GR) can act as an enhancer of SC transcription [30]. Speculatively, the reduction of ACPA SIgA in corticosteroid treated RA patients could be due to ligation of the corticosteroid with the GR followed by a lower SC transcription. In fact, reduced SC levels in BAL have been shown in a model for asthma where mice were treatment with corticosteroids [31].

We found no associations between radiographic joint damage and change in ACPA levels. As expected, baseline ACPA IgG positivity associated with radiographic progression but ACPA baseline levels did not. Although not investigating antibody levels over time, a previous Dutch study reported that baseline ACPA IgA predicted radiographic progression in RA during a 4-or 10 year follow-up [32]. In contrast, we did not find any significant association between baseline ACPA IgA and radiographic joint damage, but substantial differences in symptom duration and anti-rheumatic therapy between the cohorts could have contributed to the disparate findings. In the present study, radiographic data were only available from 155 patients. Although this is a limitation, basic characteristics and clinical outcomes were similar between patients with radiographic data and those without. Also the low proportion of patients treated with bDMARDs did not allow analysis of bDMARds effect on ACPA responses over time and although the study design included additional time points for sample collection, these time points could not be used due to drop-out.

We conclude that ACPA SIgA and IgM levels in serum decline rapidly in recent-onset RA patients during the 3 first months, and that this correlates with improved disease activity and more intense pharmacotherapy. This finding is relevant regarding
pathogenesis, but the lack of correlation with radiographic damage, and with disease activity beyond 3 months, reduces the value of analysing these isotypes in clinical routine. When comparing the change in ACPA levels upon anti-rheumatic treatment, the change in ACPA SIgA and IgA were more pronounced among patients taking oral corticosteroids or csDMARD in combination. By using CCP as antigen in the current study, we analysed multiple ACPA isotype reactivities. Therefore, forthcoming studies should address whether certain ACPA specificities of SIgA, IgA and IgM isotypes may be more intimately related to disease course.

Acknowledgments

We thank the clinical immunology unit at Linköping university hospital for performing the ACPA IgG and IgA analyses. We are also most grateful to all TIRA co-workers and participating patients. This project was funded by grants from the Swedish Society of Medicine, the Swedish research council, the Medical research council of south-east Sweden, Reinhold Sund foundation, King Gustaf V 80-year foundation, the Swedish rheumatism association, and the Östergötland county council.

Conflict of Interest

The authors declare that they have no conflict of interests.
References


10 Olas K, Butterweck H, Teschner W, Schwarz HP, Reipert B. Immunomodulatory properties of human serum immunoglobulin A: anti-inflammatory and pro-


**Figure legends**

**Figure 1**
Percentage of positive ACPA IgG, IgA, IgM and SIgA RA patients at inclusion and during the 36 months of follow-up. * P<0.05 and ** P<0.01 (McNemar test).

**Figure 2**
Mean levels of ACPA IgG, IgA, IgM and SIgA in RA patients at inclusion and during the 36 month of follow-up. **** P=0.0001 (Friedman test). Error bars represent SEM (n=231).

**Figure 3**
Relative change in levels of ACPA IgA, IgM and SIgA in early RA as compared with relative change in ACPA IgG levels (**** represent P<0.0001 and * P<0.05, Kruskal-Wallis test followed by Dunn’s multiple comparisons test).
Tables

Table 1. Baseline patient characteristics (n=231) and treatment regime started at the inclusion visit.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Women, n (%)</td>
<td>162 (70.1)</td>
</tr>
<tr>
<td>Mean age (Years± SD)</td>
<td>57.4±13.0</td>
</tr>
<tr>
<td>Rheumatoid factor positive, n (%)</td>
<td>150 (64.9)</td>
</tr>
<tr>
<td>IgG anti-CCP positive, n (%)</td>
<td>172 (74.4)</td>
</tr>
<tr>
<td>DAS28 (Mean±SD)</td>
<td>5.1±1.2</td>
</tr>
<tr>
<td>HAQ (Mean±SD)</td>
<td>1.0±0.6</td>
</tr>
<tr>
<td>Mean IgG anti-CCP level (U/ml±SEM)</td>
<td>180.2±9.7</td>
</tr>
<tr>
<td>Mean IgA anti-CCP level (µg/ml±SEM)</td>
<td>7.5±0.9</td>
</tr>
<tr>
<td>Mean IgM anti-CCP level (AU/ml±SEM)</td>
<td>9950.2±1262</td>
</tr>
<tr>
<td>Mean SIgA anti-CCP level (AU/ml±SEM)</td>
<td>3929.4±389.7</td>
</tr>
<tr>
<td>Oral corticosteroids, n (%)</td>
<td>138 (59.7)</td>
</tr>
<tr>
<td>csDMARD single therapy, n (%)</td>
<td>196 (84.8)</td>
</tr>
<tr>
<td>csDMARD combination therapy, n (%)</td>
<td>20 (8.7)</td>
</tr>
<tr>
<td>bDMARD therapy, n (%)</td>
<td>1 (0.4)</td>
</tr>
</tbody>
</table>

DAS28: disease activity score 28, HAQ: health assessment questionnaire, csDMARD: conventional synthetic disease-modifying anti-rheumatic drug (single therapy including methotrexate (MTX), salazopyrin (SSZ), antimalaria or leflunomide. combination therapy including different combinations of MTX, SSZ, antimalarial and imurel) and bDMARD: biological disease-modifying anti-rheumatic drug. a data available from 215 patients, b data available from 206 patients, c Cut-off: ACPA IgG 7U/mL, dACPA IgA 2
μg/L, ACPA IgM 6032 AU/mL and ACPA SIgA 3089 AU/mL and data available from 230 patients.

Table 2. Patient characteristics (n=231) at month 36.

<table>
<thead>
<tr>
<th></th>
<th>Mean±SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Larsen score (Mean±SD)^a</td>
<td>4.2±4.4</td>
</tr>
<tr>
<td>Larsen progress (Mean±SD)^a</td>
<td>1.8±2.8</td>
</tr>
<tr>
<td>Oral corticosteroids, n (%)</td>
<td>109 (47.2)</td>
</tr>
<tr>
<td>csDMARD single therapy, n (%)</td>
<td>138 (59.7)</td>
</tr>
<tr>
<td>csDMARD combination therapy, n (%)</td>
<td>42 (18.2)</td>
</tr>
<tr>
<td>bDMARD, n (%)</td>
<td>28 (12.1)</td>
</tr>
</tbody>
</table>

csDMARD: conventional synthetic disease-modifying anti-rheumatic drug (single therapy including methotrexate (MTX), salazopyrin (SSZ), antimalaria or leflunomide. combination therapy including different combinations of MTX, SSZ, antimalarial and imurel) and bDMARD: biological disease-modifying anti-rheumatic drug. ^a data available from 155 patients.
Table 3. Spearman correlation analysis of relative change in antibody levels in relation to DAS28 change in recent-onset RA patients (n=231).

<table>
<thead>
<tr>
<th>Months after inclusion</th>
<th>ACPA IgG Rho</th>
<th>P</th>
<th>ACPA IgA Rho</th>
<th>P</th>
<th>ACPA IgM Rho</th>
<th>P</th>
<th>ACPA SIgA Rho</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-3</td>
<td>0.242</td>
<td>0.003</td>
<td>0.260</td>
<td>0.008</td>
<td>0.457</td>
<td>0.001</td>
<td>0.402</td>
<td>0.001</td>
</tr>
<tr>
<td>3-12</td>
<td>0.271</td>
<td>0.001</td>
<td>0.171</td>
<td>0.079</td>
<td>0.276</td>
<td>0.021</td>
<td>0.240</td>
<td>0.036</td>
</tr>
<tr>
<td>12-36</td>
<td>0.232</td>
<td>0.003</td>
<td>0.056</td>
<td>0.555</td>
<td>0.210</td>
<td>0.069</td>
<td>0.018</td>
<td>0.875</td>
</tr>
</tbody>
</table>
Table 4. Spearman correlation analysis of relative change in antibody levels during the first 3 months in relation to change in DAS28 components and VAS pain in recent-onset RA patients at inclusion positive for the respective antibody.

<table>
<thead>
<tr>
<th>ACPA isotype</th>
<th>Swollen joints</th>
<th>Tender joints</th>
<th>CRP</th>
<th>ESR</th>
<th>Patient’s global assessment</th>
<th>VAS pain</th>
</tr>
</thead>
<tbody>
<tr>
<td>SIgA</td>
<td>0.355</td>
<td>0.001</td>
<td>0.426</td>
<td>0.001</td>
<td>0.304</td>
<td>0.006</td>
</tr>
<tr>
<td>IgM</td>
<td>0.344</td>
<td>0.002</td>
<td>0.488</td>
<td>0.001</td>
<td>0.395</td>
<td>0.001</td>
</tr>
<tr>
<td>IgG</td>
<td>0.201</td>
<td>0.010</td>
<td>0.200</td>
<td>0.010</td>
<td>0.105</td>
<td>0.185</td>
</tr>
<tr>
<td>IgA</td>
<td>0.243</td>
<td>0.009</td>
<td>0.130</td>
<td>0.165</td>
<td>0.265</td>
<td>0.005</td>
</tr>
</tbody>
</table>
Figure 1
Figure 3

**% of baseline antibody level**

- ACPA IgG (n=172)
- ACPA IgA (n=120)
- ACPA IgM (n=81)
- ACPA sIgA (n=85)